Company / Operating Income
NEKTAR THERAPEUTICS Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$140.1M
FY2025
5-year range
-$446.1M / -$140.1M
FY2021-FY2025
Trend
+46.9%
vs FY2024
Sector context
#109 of 204
Health Care
What the data says
At -$140M, NEKTAR THERAPEUTICS's operating income ranks #109 of 204 in the Health Care sector. Operating Income has fluctuated over the past 10 years, ranging from -$446M in FY2023 to $688M in FY2020.
Based on SEC 10-K filings.
-$140M in FY2025.
Improved from -$446M to -$140M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#109 of 204 in Health CareTop 53% of 204This company -$140.1M Sector average $107.8M
▼
-230.0% below sector average
Key checks
Key Insights
- In FY2025, operating income increased 46.9% year-over-year.
- Ranks #109 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2020.
- Lowest operating income in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$140.1M | +46.9% |
| FY2024 | -$263.7M | +40.9% |
| FY2023 | -$446.1M | -18.6% |
| FY2022 | -$376.2M | +15.7% |
| FY2021 | -$446.1M | -164.8% |
| FY2020 | $687.9M | +1253.4% |
| FY2019 | -$59.6M | +47.2% |
| FY2018 | -$112.9M | -89.2% |
| FY2017 | -$59.6M | -261.8% |
| FY2016 | -$16.5M | +43.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026